entinostat

{
  "id": "MLC-T-ONC-002859",
  "term": "entinostat",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor. Also called HDAC inhibitor SNDX-275 and SNDX-275.",
    "A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation."
  ],
  "synonyms": [
    "HDAC inhibitor SNDX-275",
    "SNDX-275",
    "KHK2375"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/entinostat/"
}